Trial Profile
An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients With Partial Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2017
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors UCB
- 03 May 2014 Long-term results from a pooled analysis presented at the 66th Annual Meeting of the American Academy of Neurology.
- 26 Feb 2013 New trial record